The upgrade from Underperform to Neutral by B of A Securities analyst Kevin Fischbeck indicates a more positive outlook on Oscar Health's stock. The raised price target from $5.4 to $8.75 suggests that the analyst believes the stock has potential for growth in the short term. This news is likely to have a positive impact on the stock price as investors may view the upgrade as a sign of improving fundamentals or prospects for the company.